Relay Therapeutics (RLAY) FCF Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported FCF Margin of 1703.73% for Q1 2026, down 74535.0% year-over-year from N/an in Q1 2025, and down 165.82% on a QoQ basis from 640.94% in Q4 2025.
Relay Therapeutics (RLAY) has 6 years of FCF Margin data on file, last reported at 1703.73% in Q1 2026.
- Quarterly FCF Margin fell 74535.0% year-over-year to 1703.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1998.53% (up 155162.0% YoY) and the FY2025 annual result came in at 1536.08%, up 97341.0% from the prior year.
- FCF Margin fell to 1703.73% in Q1 2026 per RLAY's latest filing, from 640.94% in the prior quarter.
- Across five years, FCF Margin topped out at 8930600.0% in Q4 2023 and bottomed at 58910.92% in Q2 2023.
- The 5-year median for FCF Margin is 8166.47% (2025), against an average of 673613.82%.
- Peak annual rise in FCF Margin reached 895407628 bps in 2023, while the deepest fall reached 4276024 bps in 2023.
- Tracing RLAY's FCF Margin over 5 years: stood at 23476.28% in 2022, then soared by 38141 bps to 8930600.0% in 2023, then slumped by 100 bps to 520.67% in 2024, then retreated by 23 bps to 640.94% in 2025, then slumped by 166 bps to 1703.73% in 2026.
- Per Business Quant, the three latest RLAY FCF Margin figures stand at 1703.73% (Q1 2026), 640.94% (Q4 2025), and 8166.47% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -1,703.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,703.73% |
| Dec 31, 2025 | -640.94% |
| Jun 30, 2025 | -8,166.47% |
| Mar 31, 2025 | -958.38% |
| Mar 31, 2024 | -520.67% |
| Dec 31, 2023 | 8,930,600.00% |
| Sep 30, 2023 | -301.51% |
| Jun 30, 2023 | -58,910.92% |
| Mar 31, 2023 | -30,550.88% |
| Dec 31, 2022 | -23,476.28% |
| Sep 30, 2022 | -19,837.21% |
| Jun 30, 2022 | -16,150.68% |
| Mar 31, 2022 | -12,402.63% |
| Dec 31, 2021 | -7,158.20% |
| Sep 30, 2021 | -8,215.17% |
| Jun 30, 2021 | -3,449.88% |
| Mar 31, 2021 | 4,888.66% |